Cardiex launches CONNEQT Pulse pre-orders with 20,000+ US waitlist

Cardiex opens US pre-orders for the CONNEQT Pulse, targeting consumer arterial health monitoring
Over 20,000 sign-ups on the waitlist as Cardiex rolls out exclusive pre-order invitations
Phased launch aims to streamline customer experience and drive growth in the US market

Special Report: Australian medtech Cardiex began pre-orders for its much-anticipated CONNEQT Pulse biometric monitor on Friday with exclusive invitations to US waitlist subscribers.

The news follows a highly successful waitlist campaign, where over 20,000 consumers registered their interest in the device, and marks a significant milestone in the company’s journey to bring cutting-edge cardiovascular health technology to a broader consumer base.

The Cardiex (ASX:CDX) produced CONNEQT Pulse is engineered to go beyond conventional blood pressure monitoring, providing users with detailed insights into cardiovascular health.

The device’s vascular biomarkers can measure central blood pressure, arterial stiffness, heart stress, and other advanced cardiovascular parameters, a capability that places it as the only vascular biomarker monitor on the US Blood Pressure Validated Device List.

Pivotal Moment

Cardiex CEO Craig Cooper described the launch as a defining milestone for the company.

“This is a pivotal moment as we launch the CONNEQT Pulse, bringing our patented arterial health technology directly to US consumers for the first time,” he said.

“Our pre-order rollout strategy allows us to ensure a smooth customer experience while efficiently managing demand and conversions.

“Reaching this milestone reaffirms the strength of our strategy, and we expect the positive momentum to support revenue growth and accelerate our entry into broader healthcare markets.”

Growing demand

The CONNEQT Pulse is well-positioned to meet rising demand among consumers and clinicians for comprehensive cardiovascular monitoring that provides personalised health insights.

For individuals focused on proactive health management and clinicians aiming to enhance patient care, the Pulse delivers detailed vascular data that traditional blood pressure monitors cannot match.

Beyond traditional retail, Cardiex also sees potential applications in primary care, decentralised clinical trials, and concierge healthcare practices.

The company has already won significant validation for its technology, including a recent US$525,000 grand prize from the NIH RADx Tech for Maternal Health Challenge, underscoring the potential impact of its cardiovascular solutions on global health.

This article was developed in collaboration with Cardiex, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.